Chemical athletes who want to use nandrolone to build up their muscle mass are best off choosing a preparation with a) the longest ester possible, b) the highest concentration possible and c) injecting it in their gluteus muscle instead of in their shoulders. This according to a 1997 study published by andrologists at the University of Sydney in the Journal of Pharmacology and Experimental Therapeutics.
The researchers did an experiment with 23 healthy, non-obese men aged between 18 and 40. They divided the men up into 4 groups and injected each group with a different nandrolone preparation. All preparations contained 100 mg nandrolone. Then the researchers measured the amount of nandrolone in the men’s blood each day for the next 32 days.
The first group were given an injection of 100 mg nandrolone phenylpropionate [structural formula shown above] in their buttock. Nandrolone phenyl propionate used to be an ingredient in Organon’s Durabolin, and is now found in UG preparations. Phenylpropionate is an ester that does not remain in the blood as long as decanoate. The 100 mg was in an ampoule of 4ml groundnut oil.
The second group got the same kind of injection, but containing nandrolone decanoate, the steroid in Deca-Durabolin.
The third group also got an injection containing 100 mg nandrolone decanoate in the buttocks, but this time the nandrolone was concentrated in 1 ml groundnut oil.
And finally, the fourth group were injected with 100 mg nandrolone decanoate, dissolved in 1 ml groundnut oil, in the shoulder muscle.
Nandrolone phenylpropionate gives a rapid peak in the blood, but the peak subsides after 4-5 days. Nandrolone decanoate doesn’t cause a peak, but remains present for much longer in the blood.
More nandrolone enters the blood if you inject it in a more concentrated form: 1 ml instead of 4 ml.
Injecting into the buttocks results in more nandrolone in the blood than injecting into the shoulders.
In the table below the shaded part shows the total amount of nandrolone that shows up in the blood after four separate injections. Look at the ‘area under the curve’.
The research was partly financed by Organon Australia.
Pharmacokinetics and Pharmacodynamics of Nandrolone Esters in Oil Vehicle: Effects of Ester, Injection Site and Injection Volume
Charles F. Minto1,
Christopher Howe2,
Susan Wishart2,
Ann J. Conway2 and
David J. Handelsman2
+ Author Affiliations
Department of Anaesthesia and Pain Management, Royal North Shore Hospital (C.F.M.), and 2Andrology Unit, Royal Prince Alfred Hospital, Department of Medicine (C.H., S.W., A.J.C., D.J.H.), University of Sydney, Sydney, Australia
Abstract
We studied healthy men who underwent blood sampling for plasma nandrolone, testosterone and inhibin measurements before and for 32 days after a single i.m. injection of 100 mg of nandrolone ester in arachis oil. Twenty-three men were randomized into groups receiving nandrolone phenylpropionate (group 1, n = 7) or nandrolone decanoate (group 2, n = 6) injected into the gluteal muscle in 4 ml of arachis oil vehicle or nandrolone decanoate in 1 ml of arachis oil vehicle injected into either the gluteal (group 3, n = 5) or deltoid (group 4,n = 5) muscles. Plasma nandrolone, testosterone and inhibin concentrations were analyzed by a mixed-effects indirect response model. Plasma nandrolone concentrations were influenced (P < .001) by different esters and injection sites, with higher and earlier peaks with the phenylpropionate ester, compared with the decanoate ester. After nandrolone decanoate injection, the highest bioavailability and peak nandrolone levels were observed with the 1-ml gluteal injection. Plasma testosterone concentrations were also influenced (P < .001) by the ester and injection site, with the most rapid, but briefest, suppression being due to the phenylpropionate ester, whereas the most sustained suppression was achieved with the 1-ml gluteal injection. Plasma inhibin concentrations were also significantly influenced by injection volume and site, with the lowest nadir occurring after the nandrolone decanoate 1-ml gluteal injection. Thus, the bioavailability and physiological effects of a nandrolone ester in an oil vehicle are greatest when the ester is injected in a small (1 ml vs. 4 ml) volume and into the glutealvs. deltoid muscle. We conclude that the side-chain ester and the injection site and volume influence the pharmacokinetics and pharmacodynamics of nandrolone esters in an oil vehicle in men. Source: http://jpet.aspetjournals.org/content/281/1/93.abstract